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and the implications that this entails. METHODS: It is presented as a cross-sec-
tional research, drafted in a descriptive and analytical component of data. It is
based on the application of an anonymous questionnaire to these patients, which
consists of three parts: 1) socio-demografic, clinical and disease’s characterization
data; 2) Pediatric Quality of Life Inventory Version 4.0 – PedsQLTM 4.0 and 3) Dia-
betes Quality of Life questionnaire – DQOL. The data was analyzed using SPSSâ
software – version 17 and were considered significant at p-value 0,10. RESULTS:
In total, 17 (68%) children and adolescents between 11-18 years, with an average
number of years with disease of 6,29 years, participated in this study. The dimen-
sions of PedsQLTM 4.0 “Emotional Functioning” and the “School Functioning” and
the sub-scales of DQOL “Worries about Diabetes” and “Satisfaction with treatment”
imply worst results in Health-related Quality of Life. It is observed that the vari-
ables gender, location, school performance and employment status of mother and
father can influence the level of quality of life. Moreover, this level is more satis-
factory in the presence of records related to more appropriate Body Mass index,
fewer years of disease, lower values of glycated hemoglobin type A1c and lower
number of insulin injections per day.CONCLUSIONS: It is recognized that this work
offers a partial view of the disease, but contributes to understand some implicated
factors in its control and in the level of quality of life of diabetic children and
adolescents. It is recommended that such assessments should be made regularly,
within a multi-disciplinary team which should be responsible for monitoring these
patients
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OBJECTIVES: Following the introduction of the Quality and Outcomes Framework
(QOF) in the UK there has been an increase in the number of patients below-target
HbA1c levels (HbA1c7.5%) from 39.7% to 52.1% between 2006 and 2008. However,
a substantial number of patients with type 2 diabetes mellitus (T2DM) remain
poorly controlled. This study quantifies the effect of poorly controlled T2DM on the
average number of microvascular and macrovascular events. METHODS: The Car-
diff Type 2 Diabetes Model was initiated with cohort profiles consistent with cur-
rent UK clinical practice in patients newly diagnosed with T2DM. HbA1c treatment
effects were modelled to correspond with the intensive and conventional control
groups in the UKPDS over a 20-year time horizon assuming: 1) patients achieve and
maintain target control (“controlled”), and 2) patients fail to achieve target control
(“uncontrolled”) having HbA1c levels of 7.5-9.0%. Data from primary care (THIN)
were used to categorise the number of patients by HbA1c level in those on first-line
therapy or diet and exercise whose duration of diabetes was 2 years. RESULTS:
Data from THIN demonstrated that 50% of patients had HbA1c below 7%. Of the
remaining, 20%, 13%, 7% and 10% had HbA1c readings in the following ranges:
7-7.4%; 7.5-7.9; 8-8.4 and 8.5% respectively. Compared to those controlled sub-
jects, with an HbA1c 7%, the model predicts 92, 115, 138 and 162 excess macro-
vascular and microvascular complications in those in the 7-7.4%; 7.5-7.9; 8-8.4 and
 8.5% HbA1c groups respectively. CONCLUSIONS: Given current budgetary con-
straints, an ageing population, and increasing obesity, it is imperative that patients
with T2DM are optimally managed in routine clinical practice from the outset.
Failure to manage patients appropriately will have substantial implications for
both patients and the healthcare system.
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OBJECTIVES: To assess how general practitioners (GPs) in France adapt their anti-
diabetic therapeutic strategies among type 2 diabetes mellitus (T2DM) patients
who also had chronic kidney disease (CKD). METHODS: A multi-centric cross-sec-
tional and retrospective study was undertaken, investigating patient characteris-
tics, disease severity, therapeutic strategies, reasons for changes thereof through
questionnaires filled by GPs, coupled with drug treatments extracted from the IMS
Disease Analyser database. RESULTS: The study sample included 120 T2DM pa-
tients (median age  76.0, 45% men): 37 with stage 3a CKD (45GFR60 ml/min,
median age 75.1, 57% men) and 83 with stage 3b or severe CKD (GFR45 ml/min,
median age 76.4, 38% men). Oral anti-diabetic treatments were widely prescribed
among CKD patients: of those with stage 3a and 3b, respectively 37.5% and 39.3%
had oral monotherapy, while 40.6% and 28.6% had oral double or triple therapy.
21.9% and 32.1% had insulin therapy (3 a and 3 b, respectively). 65% of patients were
treated with an anti-diabetic drug which is either contraindicated or not recom-
mended for CKD patients; GPs adapted the anti-diabetic strategy during the previ-
ous year for 43% patients, 53% of the time due to CKD. Mean HbA1c was 7.1% and
7.2% among CKD stage 3a and 3b patients, respectively; with 58% (3a) and 54% (3b)
having HbA1c7. Only 23% of patients achieved control of diabetes (GP assess-
ment), with treatment that does not include a drug either contraindicated or not
recommended for this patient group; 2/3 of these patients received insulin.
CONCLUSIONS: Treating T2DM patients with CKD remains a challenge for GPs:
data suggest that GPs are favouring glycemic control over safety by using anti-
diabetic drugs that are either contraindicated or not recommended for CKD pa-
tients. New oral treatments that would allow physicians to control glycemia while
appropriately considering impaired renal function are needed.
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OBJECTIVES: To assess the causes for referral of type 2 diabetes (T2DM) patients
from primary care (PC) to specialized care (SC) in Spain. To assess the degree of
compliance with referral quality markers established in national
guidelines/recommendations. METHODS: Observational, cross-sectional, multi-
centre national study, in PC and SC. Each physician provided data on usual practice
for T2DM patient referral and clinical status of patients with T2DM for 6 referred
patients. Inclusion criteria for patients were: written consent, previous T2DM di-
agnosis and age over 18; exclusion criteria: T1DM, MODY, LADA and secondary
diabetes. Recommendations of the Spanish Society for Endocrinology and Nutri-
tion (SEEN) and the National Health System (SNS), were used as reference docu-
ments to assess compliance. RESULTS: Data from clinical practice of 143 endocri-
nologists and 641 general practitioners (GPs), and from referrals of 805 patients to
PC and 3624 to SC are presented. PC to SC referrals: 31.8% of GPs reported the
existence of a coordination protocol with endocrinologists. The most frequent
communication tool with SC was Consultation Report (89.2%). The referral criterion
that most GPs reported to apply in usual practice was Metabolic Instability (80.5%).
The most frequent cause for referral among the patients studied was Reassess-
ment (48.4%), a criterion not included in national guidelines. 46.8% of GPs applied in
usual practice all SNS, 3.9% all SEEN referral criteria. SC to PC referrals: 46.2% of
endocrinologists reported the existence of a coordination protocol with PC. The
most frequent communication channel with PC was Medical History (47.2%). The
referral criterion reported by a higher number of endocrinologists (96.5%) was Goal
Achievement, most frequent cause for referral also among the patients studied.
CONCLUSIONS:These findings emphasise the need of improving coordination pro-
cesses to optimize and homogenize referrals. The number of reported coordination
protocols is low, and the compliance with national guidelines poor.
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OBJECTIVES: To identify patient barriers, clinical management concerns, and drug
coverage issues for elderly type 2 diabetes patients in the Medicare Part D
population METHODS: A literature review was conducted using PubMed with
searches limited to studies published in the last 2 years, in English, and in aged 65.
Searches included combinations of the following terms: diabetes mellitus, mortal-
ity, prevention and control, Medicare, diabetes management, treatment guide-
lines, control. Hand searching of clinical management guidelines and diabetes
conferences (2007-present) was conducted to identify further issues pertaining to
the research questions of interest. RESULTS: The literature search by key word
yielded 141 relevant articles, 42 of which were included after abstract review for
relevance. Literature on clinical management challenges identified a high preva-
lence of untreated disease in this patient population due to a significantly large
number of elderly type 2 diabetes patients being undiagnosed. Adherence to treat-
ment guidelines in this patient population is challenging due to the high level of
co-morbidities that may complicate the goal of intensive glucose management. As
more oral antidiabetic agents become available as treatment options, patients be-
come more likely to change therapies with more elderly patients switching from
single-agent to combination therapy. Literature on cost-sharing in Medicare Part D
and the current coverage gap suggest that patients covered under the benefit face
a high out of pocket burden for treatment and that such costs lead to medication
non-adherence and physician switching to less efficacious alternatives
CONCLUSIONS: Clinical management challenges and economic barriers to access
are more pronounced for elderly Medicare Part D than in the general population of
type 2 diabetes patients. Further insight and research are needed to explore how
policy changes for coverage and treatment guidelines may be able to address these
concerns.
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OBJECTIVES: To describe demographic and clinical characteristics of diabetic pa-
tients who initiated basal insulin and assess their glycemic control. METHODS:
Physician encounters recorded in the General Electric EMR Database (2005-2010)
were assessed. Patients with type II diabetes (T2DM) who initiated basal insulin
between February 2006 and August 2009 were selected, with initiation defined as
no prescription record of insulin in prior 15 months. Patients were followed for an
average of 2.5 years after insulin initiation, and the proportion achieving A1C7%
(“goal”) and time to achieving goal were assessed. Among patients who reached
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goal, the proportion of and time to A1C increasing above 7% (relapse) were ana-
lyzed. Cox proportional hazard models were estimated to identify demographic
and clinical predictors of A1C goal achievement and relapse. RESULTS: Basal insu-
lin initiators with T2DM (n13,373) were on average 60 years old, 50.5% were fe-
males, 59.5% had A1C8%, 59.7% were obese, and more than half used metformin
(52.7%) or sulfonylureas (53.4%) before insulin initiation. A total of 5844 (44%) pa-
tients reached goal within one year since initiation, and 7699 (58%) reached goal
during the 2.5-year follow-up. The median time to reaching goal was 536 days
(95% CI: 510-562). Older age, being white or male, lower baseline A1C values and no
OAD use before insulin initiation were associated with significantly higher rates of
reaching goal. Among the patients who reached goal, 57.6% relapsed, and the me-
dian time from reaching the goal to relapse was 398 days (95% CL: 383-417). Being
Hispanic, higher baseline A1C values and OAD use at baseline were associated with
significantly higher rates of relapse. CONCLUSIONS: A high proportion of T2DM
patients did not have adequate glycemic control after initiating basal insulin. Var-
ious factors existing prior to insulin initiation were related to successful treatment
of T2DM. Further research into how to improve glycemic control is encouraged.
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OBJECTIVES: The aim of the current study was to examine patient characteristics,
treatment patterns, and burden of type 2 diabetes (T2D) adult patients with and
without comorbid obesity in France, Germany, and UK. METHODS: Data from the
EU National Health and Wellness Survey were used. Demographics, HbA1c levels,
prevalence of hypertension, high cholesterol, T2D current treatments, and health
outcomes (SF-12) were assessed for all T2D patients (France: n642, Germany:
n1,019, UK: n932). Patients with and without obesity (BMI30) were also
compared. RESULTS: Obesity rates within T2D were 47%, 51%, and 56% in France,
Germany, and UK, respectively. Pooling countries, T2D patients had 2.6 greater
odds of obesity than non-T2D patients and the proportion of obese T2D patients
increased from 44% to 51 % (2006 to 2010). The rates of being uncontrolled (HbA1c
7%) were higher among obese T2D (20% vs. 17%, p.05), but the difference was
only significant in Germany (24% vs. 19%, p.05). The use of insulin was signifi-
cantly higher (23% vs. 16%, p.05) among obese patients, but this difference was
only significant in Germany and UK and not in France. Hypertension and high
cholesterol were significantly more prevalent in obeseT2D patients (65% vs. 51%
and 40% vs. 35%, respectively, ps.05). Hypertension differences were significant
for all countries while high cholesterol differences were only significant in Ger-
many. Obesity was associated with significantly worse physical quality of life
(France: 40 vs. 44; Germany: 39 vs. 44; UK: 37 vs. 42, respectively p.05).
CONCLUSIONS: A substantial number of T2D patients are obese. Obesity was as-
sociated with worse quality of life, and worse health outcomes including poor
glycemic control (in the case of Germany), hypertension and high cholesterol; all
these factors are CV disease risk factors. Improving obesity management will be
the key to improve health and outcomes in T2D.
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OBJECTIVES: We analyzed the impact of implementing a preauthorization policy
for Rosiglitazone (an anti-diabetic drug) use on the eligibility requirements (treat-
ment initiation and discontinuation) and patients’ HbA1c levels. METHODS: We
compared treatment patterns of diabetic patients prior to and after an implemen-
tation of a preauthorization policy for Rosiglitazone use. Data were obtained from
the Maccabi Healthcare Services’ (the second largest HMO in Israel) registry of
diabetic patients. We compared adherence to eligibility criteria in a group of pa-
tients who received Rosiglitazone without preauthorization (N1362) and patients
who received the medication with preauthorization (N824). The criteria for re-
ceiving Rosiglitazone in both groups were identical and included prior medication
[experienced patients who received drug from the sulphonylurea class in combi-
nation with Metformin for at least a three months period], and laboratory criterion
[HbA1c levels higher than 8% during the past three months]. Treatment should be
continued only if within three months from treatment initiation, the patient ac-
quired at least three packages of Rosiglitazone and a decrease of 0.8% in HbA1c
values was observed. RESULTS: Implementing preauthorization policy increased
the fulfillment of the eligibility criteria (medication and laboratory) for drug use by
41% [from 25% of patients without preauthorization to 35% with preauthorization
(p0.001)]. With regard to meeting the requirements for treatment continuation
after a three month period, there was an increase of only 6.4% in the fulfillment of
both requirements (from 37.6% to 40.0% prior and after preauthorization, respec-
tively). The average decrease in patients’ HbA1c levels was 0.6% and was similar in
both patients with and without preauthorization. CONCLUSIONS: Implementing
preauthorization for Rosigitazone resulted in an increase in meeting the require-
ments for treatment initiation and a marginal change in treatment continuation
criteria, but this increase was insufficient to achieve HbA1c target levels. However,
patients’ health was not negatively affected by this policy.
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OBJECTIVES: Type 2 diabetes, is a disease with a rising prevalence worldwide. A
major burden of this disease would be shared by developing countries like Iran.
Medications for diabetes mellitus need to be taken for the entire life and factors like
efficacy, side effects, drug interactions and cost of therapy should be consider. This
study was designed to evaluate the prescription pattern of anti-diabetic drugs in
T2DM patients from 2006 to 2009 in Iran. METHODS: A retrospective study was
undertaken on insured prescriptions during 4 years. All insured prescriptions
which were collected in special software called Rx Analyst during the study period
in the NCRUD were reviewed for prescriptions included anti-diabetic drugs. The
brand names of drugs in prescriptions were decoded to generic names, according to
standard Iran drug list.RESULTS:A total of 261,110,666 prescriptions were assessed
in which 11,637,224 were detected to be included at least one dosage form of anti-
diabetic medications. From all, 1,376,750 prescriptions had at least one injection
form of Insulin and 10,260,474 of oral anti diabetic drugs. Trend evaluation of
prescribing showed that the total number anti-diabetic medications were in-
creased from 16,158,375 in 2006 to 4,268,444 in 2009. The portion of prescriptions
with Insulin was 8%, 9%, 13% and 9% and for oral anti-diabetic drugs, it was 59%,
66%, 71% and 72%in 2006, 2007, 2008 and 2009, respectively. The total cost of Insulin
during study period was 17,134,032 US$ and for oral anti-diabetic drugs was
84,682,039 US$ from national sales data. CONCLUSIONS: According to national
sales data, total cost of anti-diabetic medications is about 100,00 times more than
cost of these drugs in prescriptions. This huge gap shows irrational use of such
medications. A multi interventional policy including educational, regulatory, man-
agerial and financial strategies for professions and public should be planed to
promote rational use of anti-diabetic medications.
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OBJECTIVES: To evaluate the distribution of pioglitazone (PIO) daily dose pre-
scribed by physicians for patients with type 2 diabetes mellitus (T2DM).METHODS:
In a retrospective cohort study using the UK MediPlus database, patients with
diagnosed T2DM who received PIO prescription between July 2008– June 2009 (ob-
servation period) were included. Medical records from 07/2007–06/2008 were used
to assess baseline conditions. Patients were grouped, according to prescriptions in
the observation period, as low-dose users who received PIO prescriptions of 15-mg
daily dose only or were down-titrated to 15 mg from a higher daily dose, and
high-dose users for the rest who received a 30 mg or higher daily dose. RESULTS:Of
1813 patients with T2DM who received a PIO prescription, 48% received at least one
15 mg prescription during the observation period. Among all PIO prescriptions,
39%, 40%, and 21% were in 15, 30, and 45 mg or higher daily dose, respectively. Per
study definitions 38% of the patients were classified as low-dose users and 62% as
high-dose users. Low-dose users were more likely to be female (56% vs. 40%) and
had a lower baseline prevalence of diabetic nephropathy (0% vs. 1%), compared to
high-dose users (p0.05). Low-dose PIO use was not associated with baseline prev-
alence of congestive heart failure, coronary artery disease, or bone fractures.
CONCLUSIONS: Low-dose PIO was prescribed in greater than one-third of PIO pre-
scriptions, regardless of patient age and major comorbidities. The reason(s) why
patients received low-dose PIO warrants further investigation.
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OBJECTIVES: This retrospective study compares annual expenditures among
T2DM patients according to treatment stage and renal function status (RFS) and
identifies determinants of costs.METHODS:T2DM patients’ records were extracted
from the EGB database, which contains ambulatory care claims for a representative
sample of the French population. Patients were classified according to treatment
stage: oral / GLP1 monotherapy, double therapy, triple therapy or insulin therapy
(either associated or not with other antidiabetics), and according to RFS (identified
using pharmacy, lab and consultation claims). Costs were estimated from the na-
tional insurance perspective and included all reimbursements except for hospitali-
sations. Annual expenditures were assessed by year (from 2005 to 2010), by treat-
ment stage and by RFS. Effects of treatment stages and RFS on expenditures by year
were analysed by means of generalised linear models, with matching on age and
gender. RESULTS: The number of patients ranged from 9,682 to 11,772 between
2005 and 2010. Annual average total reimbursements in 2010 were €3,279 (standard
error: 65.5) for monotherapy, €3,592 92.1 for double therapy, €3,803 157.2 for
triple therapy and €7,729 180.8 for insulin therapy. The same cost pattern was
found in previous years. The regression model showed that costs increased by a
ratio of 2.31 (p0.001) from monotherapy to insulin therapy, adjusted for socio-
demographic characteristics and co-treatments. Excess costs for insulin therapy
were mainly related to nursing care (increasing by a ratio of 12.16, p0.001), med-
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